P ulmonary arterial hypertension (PAH) is a life-threatening disease characterized by elevated pulmonary artery pressure caused by increased pulmonary vascular resistance, ultimately leading to right heart failure and death.
the bone morphogenetic proteins, and platelet-derived growth factor [PDGF]), and soluble mediators, such as endothelin and serotonin being attributed key roles in promoting increased PASMC mass. 2 Many of these mediators are thought to be produced by other vascular cell types, including adventitial fibroblasts 4, 5 and endothelial cells, 6 which exert paracrine control of PASMC growth. Aberrant endothelial cell growth also contributes to the formation of obstructive plexiform lesions. 7 Comparatively, fewer studies (such as pioneering work by Kerr et al 8, 9 ) have addressed a role for perturbed ECM metabolism in pulmonary vascular remodeling 10 although ECM constituent proteins, such as collagen, elastin, fibronectin, and proteoglycans, play a pivotal role in cell migration, proliferation, and differentiation, which are likely to affect vessel wall remodeling. 11 It has been well established that gene expression, 12, 13 deposition, 14 and localization 15 of collagen and elastin in the pulmonary vasculature are altered in PAH. In addition, modulating proteolytic processes, which can affect vascular matrix turnover, can attenuate the course of experimental PAH. 16 However, to date, few studies have examined a role for the ECM assembly machinery in the development of PAH. To this end, we have examined the expression and function of the lysyl oxidase family of ECM cross-linking enzymes in clinical and experimental PH.
Lysyl oxidases are copper-dependent amine oxidases, which catalyze the oxidative deamination of lysine and hydroxylysine residues, generating reactive semialdehydes that condense to form intramolecular and intermolecular covalent cross-links in elastin and collagen molecules. 17 This process drives fiber maturation, imparting structural stability to the ECM. Five lysyl oxidases have been described to date, including the archetypical member, Lox, as well as 4 closely related, or Lox-like (LoxL) members, named LoxL1 to LoxL4, 17 and all lysyl oxidases are capable of initiating collagen and elastin cross-linking. 18 In this study, we describe the dysregulated expression of lysyl oxidases in multiple forms of clinical PH, including idiopathic PAH (IPAH), as well as chronic thromboembolic PH (CTEPH), and PAH caused by ventricular septal defect (VSD). We further establish a causal role for lysyl oxidases in the development of hypoxia-induced PH and hypoxia-associated pulmonary vascular remodeling. These studies thus highlight an important role-that can be pharmacologically manipulated-for perturbed ECM assembly in the aberrant vascular remodeling associated with PH.
Methods
Materials and Methods are available in the online-only Supplement.
Results

Lysyl Oxidase Expression Is Dysregulated in All Forms of PH
The expression of all 5 lysyl oxidases was assessed in lung tissues from apparently healthy human lung donors, as well as in lung tissue from patients with various forms of PH, including IPAH, CTEPH, and PAH caused by VSD (Table 1) . Relative mRNA levels, as assessed by real-time reverse transcriptasepolymerase chain reaction, revealed increased expression of the LOX (ΔΔCt ≈3.18, thus ≈9.2-fold increase; Figure 1A ), LOXL1 (ΔΔCt ≈1.95, thus ≈3.9-fold increase; Figure 1B ), LOXL2 (ΔΔCt ≈1.47, thus ≈2.8-fold increase; Figure 1C ), and LOXL4 (ΔΔCt ≈1.13, thus ≈2.2-fold increase; Figure 1D ) genes in IPAH lung tissue when compared with control donor tissue. No changes were observed for LOXL3 gene expression ( Figure IIA in the online-only Data Supplement) or for LOXL3 protein expression ( Figure IIB and IIC in the online-only Data Supplement). Immunoblot analysis confirmed an increase in the LOX and LOXL2 protein expression in IPAH lung tissue ( Figure 1E , quantified densitometrically in Figure 1F ). In addition, LOX gene expression was increased in lung tissues from patients with CTEPH (ΔΔCt ≈2.68, thus ≈ 6.4-fold increase; Figure IIIA in the online-only Data Supplement), whereas LOXL4 gene expression was decreased in lung tissue from patients with VSD (ΔΔCt ≈-1.25, thus ≈2.4-fold decrease; Figure IIIE in the online-only Data Supplement). Taken together, these data indicate that the expression of lysyl oxidases is dysregulated in multiple forms of clinical PAH. It should be kept in mind that the effect of chronic pharmacological therapy on gene expression levels has not been assessed in this study.
Lysyl Oxidase Expression Is Dysregulated in the Pulmonary Vasculature of Patients With IPAH
Both plexiform and concentric lesions were identified in sections of lung tissue from patients with IPAH, where increased smooth muscle cell mass and perturbed internal elastic laminae were evident by α-smooth muscle actin and elastin staining, respectively, when compared with nonremodeled vessels in healthy control tissue (Figure 2 ). Pulmonary arteries from healthy lung donors and both plexiform and concentric vascular lesions were then screened by immunohistochemistry for protein localization of all 5 lysyl oxidases. The expression of all lysyl oxidases was detected in donor vessels and in both plexiform and concentric lesions from patients with IPAH ( Figure 2 ). Pulmonary vessels (outer diameter, ≤150 μm) were laser-capture microdissected from donor and from lungs of patients with IPAH ( Figure 3A-3D) , and mRNA pools were screened for relative gene expression levels by quantitative real-time reverse transcriptase-polymerase chain reaction. Expression levels of the LOXL2 ( Figure 3G ) and LOXL3 ( Figure 3H ) genes were increased in the pulmonary vasculature of lungs of patients with IPAH, and expression levels of LOX also tended toward increased expression ( Figure 3E ). LOXL4 could not be detected in microdissected samples. These data indicate that the expression of lysyl oxidases is upregulated in remodeled vascular lesions associated with IPAH. Figure 3I ) and adventitial fibroblasts (ΔCt ≈7; Figure 3J ). The expression of LOX was hypoxia-responsive in both PASMC ( Figure 3I ) and adventitial fibroblasts ( Figure 3J ) from both donor and patient lungs, with a dramatic ΔΔCt of ≈3.5 (thus ≈ 11.3-fold increase). In addition, the hypoxia responsiveness of LOX in adventitial fibroblasts was more pronounced in fibroblasts isolated from lungs of patients with IPAH than from donor lungs ( Figure 3J ). Both LOXL1 (Figure 3 L) and LOXL2 ( Figure 3N ) were also hypoxia-responsive in adventitial fibroblasts. Baseline LOXL4 levels were elevated in PASMC from patients with IPAH under normoxic conditions when compared with PASMC from donors ( Figure 3Q ). Together, these data indicate that lysyl oxidases are expressed in the constituent vascular cell types of the pulmonary vasculature, that lysyl oxidase expression can be regulated by low oxygen tensions, and that lysyl oxidase expression is dysregulated in cells from patients with IPAH when compared with cells harvested from healthy lung donors.
Lung Lysyl Oxidase Expression Is Upregulated in Animal Models of PAH
The regulation of lysyl oxidase expression by hypoxia in isolated cells in vitro prompted us to explore lysyl oxidase expression in a well-established hypoxia-based model of PH. Mice exposed to normobaric hypoxia (10% O 2 in inspired gas) exhibited a rapid (within 3 hours) and dramatic increase in lox (ΔΔCt ≈2.61, thus ≈6.1-fold increase), loxl2 (ΔΔCt ≈1.38, thus ≈2.6-fold increase), and loxl4 (ΔΔCt ≈0.69, thus ≈1.6-fold increase) gene expression in lung tissue ( Figure 4A ) when compared with normoxia-treated controls. This trend was largely preserved after a 24-hour exposure to hypoxia: lox (ΔΔCt ≈2.64, thus ≈6.2-fold increase) and loxl2 (ΔΔCt ≈1.00, thus ≈2.0-fold increase; Figure 4B ). The increase in lox gene expression persisted over the entire time-course of hypoxic exposure, up to day 21, when the experiment was terminated (ΔΔCt ≈1.88, thus ≈3.7-fold increase; Figure 4C ). These data confirm that, in addition to lung tissue from patients with IPAH, the expression of lysyl oxidases was also dysregulated-and followed similar trends-in the lungs of mice with hypoxia-induced PH. Interestingly, no changes in lysyl oxidase expression were observed in the microdissected lung parenchyma of hypoxia-exposed mice, revealing that vascular (and maybe airway) perturbations to lysyl oxidase expression did not carry across to the lung parenchyma ( Figure IV in the online-only Data Supplement). The expression of lysyl oxidases was also assessed in lung homogenates and isolated PASMC from rats in which PH 
Inhibition of Lysyl Oxidase Attenuates Hypoxia-Induced PH
The rapid (within 3 hours), dramatic (3.7-to 6.2-fold), and persistent (21 days) increase in lysyl oxidase expression in the lungs of mice exposed to hypoxia suggested that lysyl oxidases might play a causal role in the development or persistence of PH. For this reason, the broad-spectrum inhibitor of lysyl oxidases, β-aminopropionitrile, was administered to mice concomitantly with hypoxia exposure. Mice exposed to hypoxia developed PH, as evident by an increased RVSP Table 1 .
( Figure 4D ) from 20.9±1.2 mm Hg in normoxia-exposed mice to 32.3±5.7 mm Hg in hypoxia-exposed mice. In mice that were treated daily with β-aminopropionitrile during hypoxia exposure at a dose of 150 mg β-aminopropionitrile/ kg body mass, the RVSP at 21 days was partially normalized, at 26.5±3.3 mm Hg. The increased RVSP was accompanied by a significant increase in the Fulton Index, as an indicator of right ventricular hypertrophy ( Table 2 ). Treatment of Figure IB to IF in the online-only Data Supplement.
mice with β-aminopropionitrile for the 21-day course of hypoxia exposure attenuated the right ventricular hypertrophy driven by hypoxia, significantly reducing the Fulton Index ( Figure 4E ). In contrast, there was no effect of hypoxia or β-aminopropionitrile on systemic arterial pressure (not shown). An increase in hematocrit was consistent with chronic exposure to hypoxia ( Figure 4F ). Thus, β-aminopropionitrile administration was able to reduce the effect of a hypoxic environment on RVSP appreciably, demonstrating a causal role for lysyl oxidase activity in the development of PH in response to chronic hypoxia. It is likely that β-aminopropionitrile functions by inhibiting lysyl oxidase activity. However, β-aminopropionitrile has been accredited with transcriptional regulatory roles, which pointed us to examine the gene expression levels of lysyl oxidases in β-aminopropionitriletreated mice. Remarkably and in line with previous studies, 19 β-aminopropionitrile administration did lead to depleted lox mRNA levels in β-aminopropionitrile-treated mice ( Figure   VIII in the online-only Data Supplement). Thus, the ability of β-aminopropionitrile administered to mice to limit collagen cross-linking induced by hypoxia may be attributed either to direct enzymatic inhibition of lysyl oxidase activity or to reduce transcription of lysyl oxidase-encoding genes, or a combination of both ( Table 2) .
Inhibition of Lysyl Oxidase Attenuates HypoxiaInduced Pulmonary Vascular Remodeling
Increased pulmonary vascular resistance as a consequence of pathological vascular remodeling underlies the development of elevated pulmonary artery pressure in PH. For this reason, the effect of β-aminopropionitrile on small pulmonary artery muscularization was assessed. After 21 days, hypoxia-exposed mice exhibited increased remodeling of small (≤70 μm) intra-acinar pulmonary arteries when compared with normoxia-exposed mice (compare Figure 5A and 5B). These changes were largely absent Table 1 ) and 3 patients with IPAH (closed bars; patients 13, 14, and 15 in Table 1 ) maintained in culture in a 21% O 2 or 10% O 2 headspace gas for 24 hours and screened for relative mRNA expression levels of lysyl oxidase family members by quantitative real-time reverse transcriptase-polymerase chain reaction. Values represent mean ΔCt±SD, referenced to the hydroxymethylbilane synthase (HMBS) gene. Two-group comparisons (donor vs patient) were made with an unpaired Student t test, whereas comparisons of multiple groups were made by 1-way ANOVA with Tukey post hoc test.
in hypoxia-exposed mice that concomitantly received β-aminopropionitrile ( Figure 5C ). Indeed, in hypoxiaexposed mice, the proportion of nonmuscularized small pulmonary arteries was approximately doubled from 6.55±1.98% in placebo-treated hypoxia-exposed mice to 17.25±7.45% in β-aminopropionitrile-treated hypoxiaexposed mice, which was not significantly different from the proportion of 23.18±3.72% observed in placebo-treated normoxia-exposed mice ( Figure 5D ). These data indicate that β-aminopropionitrile administration could attenuate the pathological vascular remodeling of small pulmonary arteries that was induced by exposure to hypoxia, which most likely accounts for the improved pulmonary hemodynamics observed in β-aminopropionitrile-treated mice.
Inhibition of Lysyl Oxidase Attenuates Perturbations to Vascular Matrix Structure
Exposure to hypoxia is known to promote collagen and elastin accumulation in the vascular walls of pulmonary arteries. 12, 15 Treatment of mice with β-aminopropionitrile appreciably reduced vascular wall thickness and elastin fiber density in small intra-acinar pulmonary arteries, comparing placebo-treated mice exposed to hypoxia ( Figure 5E and 5F) with β-aminopropionitrile-treated mice exposed to hypoxia ( Figure 5G and 5H) . These data indicate that in addition to the previously reported hypoxia-driven increases in elastin accumulation in the vessel wall, 15 lysyl oxidases also clearly play a role in determining the structure of the elastin fibers in remodeled small pulmonary arteries of hypoxia-exposed mice with PH. 
Inhibition of Lysyl Oxidase Attenuated HypoxiaDriven Perturbations to Collagen Cross-Linking
The changes to vascular matrix structures provoked by hypoxia and partially reversed by β-aminopropionitrile administration ( Figure 5E -5H) suggested that the inhibition of lysyl oxidases with β-aminopropionitrile may modulate the effect of hypoxia on collagen and elastin cross-linking. The abundance of both total collagen per lung ( Figure 6A ) and total elastin per lung ( Figure 6B ) was increased in the lungs of hypoxia-exposed mice, as was the abundance of total protein per lung ( Figure 6C ). Hypoxia drove an increase in the abundance of the sum of collagen cross-links in the total collagen pools isolated from the lungs of hypoxia-exposed mice ( Figure 6D) . A more detailed analysis of the collagen crosslink abundance revealed that these changes were limited to the rapidly (over hours) generated intermediate collagen crosslinks, where the abundance of dihydroxylysinonorleucine 1 was increased ( Figure 6E ) and the abundance of hydroxylysinonorleucine was not significantly changed ( Figure 6F ). There was no effect of hypoxia on the abundance of the slowly (over weeks) generated mature collagen cross-links, hydroxylysylpyridinoline and histidinohydroxylysinonorleucine (Table 3) . Administration of β-aminopropionitrile to mice during the 21-day course of exposure to hypoxia largely normalized the abundance of the sum of collagen cross-links isolated from the lungs of hypoxia-exposed mice ( Figure 6D ) and also largely normalized the abundance of dihydroxylysinonorleucine ( Figure 6E ) with the abundance of hydroxylysinonorleucine not significantly changed ( Figure 6F ). In contrast, β-aminopropionitrile was without the effect on the abundance on hydroxylysylpyridinoline and histidinohydroxylysinonorleucine (Table 3) . There was no effect of hypoxia, or indeed of β-aminopropionitrile, on the abundance of the elastin crosslinks, desmosine or isodesmosine (Table 4) . Taken together, these data demonstrate that exposure of adult mice to hypoxia drives increased collagen abundance and collagen cross-link formation, notably of the rapidly generated cross-links, dihydroxylysinonorleucine and hydroxylysinonorleucine, but does not affect lysyl oxidase-mediated cross-linking of elastin. Furthermore, β-aminopropionitrile treatment can attenuate Figure 4 . A-C, Sections were stained for α-smooth muscle actin (purple) and von Willebrand factor (brown) and counterstained with methyl green. D, The proportion of small (<70 μm) vessels that were non-, partially, or fully muscularized was determined (n=6, per group). Comparisons between groups were made by 1-way ANOVA with Tukey post hoc test. E-H, Lung sections were prepared from mice 21 days after continuous exposure to hypoxia with or without BAPN treatment (described in the legend of Figure 4 ). Sections were stained for elastin using Hart elastin stain counterstained with 0.1% (m/v) Nuclear Fast Red in 0.5% (m/v) aluminum sulfate. Illustrated are representative small intra-acinar pulmonary arteries from a placebo-treated (E and F) and a BAPN-treated mouse (G and H) maintained in a hypoxic environment for 21 days.
the effect of hypoxia on collagen deposition and collagen cross-linking. 1 The nomenclature refers to the reduced variants of these intermediate cross-links.
Discussion
The data presented here demonstrate that lysyl oxidase expression was dysregulated in the lungs of patients with IPAH, CTEPH, and PAH caused by VSD. The expression of lysyl oxidases was also upregulated in vascular lesions associated with IPAH. As is evident from Table 1 , all patients were chronically medicated, and we cannot rule out that the drugs administered to these patients may have also affected lysyl oxidase expression because the effect of the pharmacological agents on transition of lysyl oxidase-encoding genes has not been established. All 5 lysyl oxidases were expressed in PASMC and adventitial fibroblasts. In PASMC, LOX was induced by hypoxia; and in adventitial fibroblasts, LOX, LOXL1, and LOXL2 were induced by hypoxia. Interestingly, the induction of LOX expression by hypoxia was more pronounced in isolated adventitial fibroblasts from patients with IPAH when compared with those from lung donors. In addition, baseline levels of LOXL4 expression were higher in isolated PASMC from patients with IPAH than those from lung donors. These data point to intrinsic differences in the regulation of lysyl oxidases in patients with IPAH when compared with donors. These data promoted us to explore a possible causal role for lysyl oxidases in PH, and this study was undertaken in a mouse model of hypoxia-induced PH, where lysyl oxidase activity was blocked by the broad-spectrum lysyl oxidase inhibitor, β-aminopropionitrile.
Mice exposed to hypoxia exhibited a rapid and dramatic increase in the expression of lox and loxl2, as early as 3 hours after exposure. Increased lox and loxl2 expression persisted for 24 hours, and the elevated lox expression persisted over Figure 6 . Both exposure to hypoxia and β-aminopropionitrile (BAPN) administration can modulate the abundance of matrix molecules and the abundance of collagen cross-links in the lung. The abundance of (A) total collagen, (B) total elastin, (C) total protein, (D) total collagen cross-links (per units collagen), (E) the dihydroxylysinonorleucine (DHLNL) collagen cross-link (per unit collagen), and (F) the hydroxylysinonorleucine (HLNL) collagen cross-link (per unit collagen) assessed in mice, 21 days after continuous exposure to normoxia or hypoxia, with or without BAPN administration, as described in the legend of Figure 4 . Comparisons between groups were made by 1-way ANOVA with Tukey post hoc test. Additional collagen and elastin cross-link data are presented in Tables 3 and 4 , respectively. Additional cross-link data are presented in Figure 6 . BAPN indicates β-aminopropionitrile; DHLNL, dihydroxylysinonorleucine; HHL, histidinohydroxylysinonorleucine; HLNL, hydroxylysinonorleucine; and HP, hydroxylysylpyridinoline.
the entire duration of the hypoxia exposure (21 days). Mice exposed to a hypoxic environment that were concomitantly treated with β-aminopropionitrile exhibited improved pulmonary hemodynamics and attenuated right ventricular hypertrophy, which developed as a consequence of perturbed pulmonary hemodynamics. In addition, β-aminopropionitrile administration to hypoxia-exposed mice reduced vascular remodeling and seemed to have reduced vascular matrix deposition when compared with placebo-treated controls. These data demonstrate that the (1) increased expression of lysyl oxidases in the lungs of hypoxia-exposed mice played a causal role in the pulmonary vascular remodeling associated with exposure to hypoxia and (2) dose of β-aminopropionitrile used was sufficient to interfere with, and indeed normalize, matrix cross-linking. Clearly, β-aminopropionitrile is a broadspectrum lysyl oxidase inhibitor, and as such, no specific role can be ascribed to a particular lysyl oxidase in the pulmonary vascular remodeling associated with hypoxia exposure. Implication of particular lysyl oxidases in this process awaits the generation of transgenic animals or the development of enzyme-specific inhibitors.
Although the mouse model of hypoxia-induced PH has its limitations when extending observations to human disease, 20 the increase in LOX and LOXL2 expression in lungs from patients with IPAH paralleled the trends observed with lox and loxl2 in hypoxia-exposed mice, lending credence to our suggestion that lysyl oxidases may participate in a vascular remodeling mechanism common to clinical and experimental PH. This idea is further supported by observations made in a second animal model of PH, the rat monocrotaline model, where increased lung expression of lox was noted in the lungs and PASMC from rats that developed PH in response to monocrotaline administration.
Levels of lysyl oxidase are directly correlated with elastin and collagen cross-linking and elastin and collagen fiber structure and stability. For example, targeted deletion of the lox gene, which causes perinatal lethality, also causes extended fragmentation of elastic fibers and discontinuities of both internal elastic lamina and lamellae in lox -/-mice. 21, 22 In addition, lox -/-mice also exhibit disruption of vascular smooth muscle cell contact and detachment of endothelial cells from the basal lamina, as well as alterations to endothelial cell morphology. 21, 22 Therefore, it is not surprising that lox -/-mice have a high incidence of aortic aneurysms, aortic tortuosity, and aortic rupture. It follows that increased expression of lysyl oxidases, over and above normal expression levels, might have the opposite effect. Although vascular stiffness is often attributed to a paucity of vascular elastin, we propose here that an overabundance of ECM cross-linking enzymes may lead to increased cross-linking of matrix molecules aberrantly, such as the increased collagen cross-linking described in the present study, in lungs from hypoxia-exposed mice, perhaps resulting in a more dense fiber network (as is clearly evident in Figure 5E -5H). Fibers that are too dense may also result in well stiffening or rigidification of the vessel wall, attributable not to paucity, but rather to an over-cross-linked ECM.
In support of such an idea, patients with chronic heart failure exhibit elevated lysyl oxidase levels, which correlate with both increased collagen cross-linking and increased left ventricular chamber stiffness. 23 More recent studies have underscored the importance of lysyl oxidase-mediated collagen cross-linking in heart failure, by demonstrating that elevated filling pressures in patients with hypertension with stage C chronic heart failure correlate not with total collagen but rather with the degree of collagen cross-linking in the myocardium. 24 The data we report here demonstrate that in the hypoxia model of PH, exposure of mice to hypoxia drives the increased cross-linking of collagen by the rapidly synthesized bifunctional collagen cross-links, dihydroxylysinonorleucine and hydroxylysinonorleucine. These cross-links are generated within hours and typically reflect newly synthesized collagen. 25 These cross-links serve as precursors for the mature trifunctional collagen cross-links, hydroxylysylpyridinoline (from dihydroxylysinonorleucine) and histidinohydroxylysinonorleucine (from hydroxylysinonorleucine) that are generated slowly (after weeks) and represent collagen maturation. 26 The observed increase in dihydroxylysinonorleucine and hydroxylysinonorleucine in response to hypoxia is consistent with these bifunctional cross-links being generated during a short (3 weeks) time-course, as is the reduction in the abundance of these cross-links after a 3-week β-aminopropionitrile administration regimen. It is evident from Table 3 that the abundance of the mature trifunctional hydroxylysylpyridinoline and histidinohydroxylysinonorleucine cross-links (measured per unit collagen) after 3 weeks of hypoxia exposure was unchanged. This most likely reflects the generation of new collagen, stimulated by hypoxia exposure, that would not yet have formed the slowly generated trifunctional hydroxylysylpyridinoline and histidinohydroxylysinonorleucine cross-links.
Neither hypoxia nor β-aminopropionitrile seemed to affect the abundance of desmosine or isodesmosine crosslinks in lung elastin (Table 4 ) although hypoxia did drive increased elastin production per se. These data may suggest that under normoxic condition, the elastin is already maximally cross-linked; however, these data do not rule out additional cross-linking by other matrix cross-linking systems, such as the transglutaminases, which have not been addressed in this study. In addition to an effect of vessel stiffening or rigidification, an abnormally stabilized (through abnormally high cross-linking) ECM may also generate matrix fibers that are resistant to proteolysis, and thus, resistant to normal vascular remodeling and turnover processes. Indeed, hypercross-linking of collagen fibers in tissue-engineered arteries through stimulation of lysyl oxidase activity increased the stability of collagen fibers to proteolysis. 27 It is well recognized that a delicate balance exists among matrix production, deposition, and degradation, in response to vascular injury, 28 and a remodeling-resistant matrix may contribute to the persistence of aberrant matrix structures in the vascular wall. It is also worth noting that matrix remodeling events regulate the behavior of cells in the local environment, by releasing matrix bound growth factors, and proteolytically released fragments of matrix molecules, such as endostatin, which can inhibit local endothelial cell proliferation and migration. 29 Protease-resistant matrix components would disturb these processes. Although the increased collagen cross-linking reported here may seem moderate (≈20% over normal), it should be borne in mind that values reflected abnormal crosslinking has developed ≥21 days and is measured against the background of normal pre-existing cross-links.
Although lysyl oxidase inhibition seems to be beneficial in the context of hypoxia-induced pulmonary vascular remodeling, β-aminopropionitrile has also been reported to worsen certain types of cardiovascular disease (eg, in an experimental animal model of abdominal aortic aneurysm). 30 In that study, lysyl oxidases were thought to provide a protective or compensatory mechanism against aneurysm formation, and indeed, it was proposed that therapeutic strategies to overexpress support the cross-linking of soluble matrix proteins (by lysyl oxidase overexpression) were proposed with the aim of stabilizing the aneurysm.
A spectrum of matrix-independent roles has also been suggested for lysyl oxidases in the cardiovascular system, which might be relevant to the onset or progression of PH. 31 LOX is a potent chemoattractant for both vascular smooth muscle cells and fibroblasts. 32 LOX activity also modulates the sensitivity of smooth muscle cells and fibroblasts to other chemoattractants, such as PDGF-BB, by oxidizing cell surface receptors, including PDGF receptor-β. 32 Thus, local production of lysyl oxidases by constituent cells of the vascular wall may drive neointimal formation or medial hypertrophy by direct recruitment of vascular smooth muscle cells. This would be consistent with the LOX-dependent vessel wall muscularization we report in this study. Along these lines, LOX is also potently chemotactic for monocytes, 33 which are emerging as important contributors to pulmonary vascular remodeling associated with hypoxia, 34 together with other inflammatory processes relevant to pulmonary vascular remodeling, 35 which may also be affected by the chemotactic properties of lysyl oxidases.
Lysyl oxidases can act as transcriptional regulators, having been identified in the nucleus of fibrogenic cells, 36 and LOX can directly activate both the collagen III 37 and the elastin 38 promoters. As discussed above, increased abundance of ECM in vessel walls is known to increase pulmonary artery stiffness, as demonstrated for extralobar pulmonary artery stiffening in hypoxia-induced PH. 39 These observations, combined with the trends in lysyl oxidase expression we report here, suggest that upregulation of lysyl oxidase expression in the pulmonary vasculature may drive increased collagen and elastin production, and thereby contribute to increased vessel stiffening. In support of this idea, lox mRNA expression correlated with RVSP in hypoxia-exposed mice. Furthermore, concomitant treatment of hypoxia-exposed mice with β-aminopropionitrile treatment normalized collagen crosslinking and RVSP and also reduced right heart hypertrophy associated with elevated RVSP.
How lysyl oxidase expression is regulated in the pulmonary vasculature remains to be clarified. We demonstrate here that LOX is hypoxia-inducible in PASMC and that LOX, LOXL1, and LOXL2 are hypoxia-inducible in adventitial fibroblasts ( Figure 3 ). However, in the absence of hypoxic stimuli, other regulatory mechanisms may drive lysyl oxidase expression in the pulmonary vasculature of patients with PAH. PDGF, a pathogenic factor and a validated therapeutic target in IPAH, 40 potently upregulated LOX expression in aortic smooth muscle cells. 41 The expression of lysyl oxidases is also regulated by transforming growth factor-β 42 and dysregulated by transforming growth factor-β signaling has been causally implicated in experimental PH. 43, 44 Thus, the increased expression of lysyl oxidases in lung tissues and vessels of patients with IPAH may results from increased PDGF or transforming growth factor-β signaling in these patients.
In this study, we hypothesized that lysyl oxidase expression and activity was dysregulated in PH. The data we report here indicate that the expression of lysyl oxidases is indeed dysregulated in both clinical PH (IPAH, CTEPH, and VSD) and hypoxia-induced PH in mice. Furthermore, a causal role for lysyl oxidase activity was confirmed in hypoxia-induced PH, and the lung matrix cross-linking systems have been validated as candidate targets for intervention with the aim of normalizing elevated pulmonary artery pressures.
In another recent report, copper chelation was demonstrated to dampen endothelial cell proliferation in the context of PAH. 45 Copper chelation would also inhibit lysyl oxidases, suggesting that lysyl oxidases may directly affect the proliferation of the constituent cells of the vessel wall; however, a specific role for lysyl oxidases in endothelial cell proliferation was not addressed in that study.
We propose that the elevated lysyl oxidase activity in the pulmonary vasculature contributes to the persistence and overabundance of ECM components (such as collagen and elastin fibers), resulting in fibers that are improperly remodeled (over-cross-linked), thereby contributing to vascular disease. These fibers are also most likely resistant to proteolytic degradation, which disturbs the delicate balance between matrix synthesis and degradation that accompany vascular injury. 28 As such, this report introduces a new player in the molecular mechanisms underlying pulmonary vascular remodeling associated with PH. The ease of targeting lysyl oxidases pharmacologically makes this family of matrix remodeling enzymes particularly interesting candidates for further investigation in pulmonary vascular disease.
